The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: GSK executive lowers stake

Tue, 12th Feb 2019 15:31

(Sharecast News) - GlaxoSmithKline company Victoria Whyte disposed of 5,199 ordinary shares in the UK's biggest drugs company on Tuesday.Whyte, who joined GSK's corporate secretariat more than 30 years ago, sold the shares at an average price of 1,553.80p each, for a total transaction value of £80,782.06.Just last week, GlaxoSmithKline reported full-year sales of more than £30bn last Wednesday but warned that earnings in the current year would be hurt by generic competition to its blockbuster asthma treatment.GSK revealed 2018 group sales were £30.8bn, for a 2% increase on the previous year, while pre-tax profits were ahead by 36% at £4.8bn.Fourth-quarter sales came in at £8.2bn and adjusted earnings per share at 31.2p. Analysts had been looking for adjusted EPS of around 27.7p.As of 1630 GMT, GSK shares had picked up 0.40% to 1,551.80p.Top Director BuysGb Group (GBG)Director name: Rasche,David AAmount purchased: 48,780 @ 410.00pValue: £199,998.00Gb Group (GBG)Director name: Clark,ChrisAmount purchased: 39,024 @ 410.00pValue: £159,998.40Gb Group (GBG)Director name: Wilson ,David John Amount purchased: 37,972 @ 410.00pValue: £155,685.20Gb Group (GBG)Director name: Brown,NickAmount purchased: 37,971 @ 410.00pValue: £155,681.10Gb Group (GBG)Director name: Catchpole ,Liz Amount purchased: 12,195 @ 410.00pValue: £49,999.50Gb Group (GBG)Director name: Eggberry ,Charmaine Amount purchased: 9,756 @ 410.00pValue: £39,999.60Cranswick (CWK)Director name: Smith,TimAmount purchased: 1,500 @ 2,585.00pValue: £38,775.00Baillie Gifford Shin Nippon (BGS)Director name: Donaldson,Michael NeilAmount purchased: 859 @ 173.75pValue: £1,492.51F&c Investment Trust (FCIT)Director name: Bone,RogerAmount purchased: 147 @ 675.79pValue: £993.41Blackrock Throgmorton Trust (THRG)Director name: Beart,SimonAmount purchased: 149 @ 497.00pValue: £740.53Blackrock Throgmorton Trust (THRG)Director name: Beart,SimonAmount purchased: 149 @ 497.00pValue: £740.53F&c Investment Trust (FCIT)Director name: Hewitt,JeffreyAmount purchased: 74 @ 675.79pValue: £500.08Qinetiq Group (QQ.)Director name: Smith,DavidAmount purchased: 66 @ 306.32pValue: £202.17Qinetiq Group (QQ.)Director name: Wadey ,Steve Amount purchased: 65 @ 306.32pValue: £199.11United Utilities Group (UU.)Director name: Houlden,RussAmount purchased: 23 @ 824.37pValue: £189.61United Utilities Group (UU.)Director name: Mogford,Steven LAmount purchased: 22 @ 824.37pValue: £181.36Jpmorgan Japan Smaller Companies Trust (JPS)Director name: Henderson,AlexaAmount purchased: 50 @ 361.20pValue: £180.60United Utilities Group (UU.)Director name: Fraser,StevenAmount purchased: 21 @ 824.37pValue: £173.12Easyjet (EZJ)Director name: Findlay ,Andrew Amount purchased: 12 @ 1,290.00pValue: £154.80Arden Partners (ARDN)Director name: Clive Reed-Daunter,James (Jim)Amount purchased: 555 @ 27.00pValue: £149.85Arden Partners (ARDN)Director name: Brown,Donald Amount purchased: 555 @ 27.00pValue: £149.85Cobham (COB)Director name: Mellors,DavidAmount purchased: 132 @ 113.20pValue: £149.42Cobham (COB)Director name: Lockwood,DavidAmount purchased: 132 @ 113.20pValue: £149.42Oxford Instruments (OXIG)Director name: Barkshire,Ian Amount purchased: 15 @ 955.00pValue: £143.25Oxford Instruments (OXIG)Director name: Hill,GavinAmount purchased: 15 @ 955.00pValue: £143.25Glaxosmithkline (GSK)Director name: Redfern,David Amount purchased: 8 @ 1,554.33pValue: £124.35Glaxosmithkline (GSK)Director name: Walmsley,EmmaAmount purchased: 8 @ 1,554.33pValue: £124.35Glaxosmithkline (GSK)Director name: Whyte,VictoriaAmount purchased: 8 @ 1,554.33pValue: £124.35Glaxosmithkline (GSK)Director name: Dingemans,SimonAmount purchased: 8 @ 1,554.33pValue: £124.35F&c Investment Trust (FCIT)Director name: Knapp,EdwardAmount purchased: 15 @ 675.79pValue: £101.37Cobham (COB)Director name: Colloff,Lyn Amount purchased: 89 @ 113.20pValue: £100.75Top Director SellsStenprop Limited (STP)Director name: Carey,Julian Amount sold: 105,000 @ 112.13pValue: £117,731.25Glaxosmithkline (GSK)Director name: Whyte,VictoriaAmount sold: 5,199 @ 1,553.80pValue: £80,782.06
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.